187 related articles for article (PubMed ID: 16831932)
1. Bone destruction in multiple myeloma.
Matsumoto T; Abe M
Ann N Y Acad Sci; 2006 Apr; 1068():319-26. PubMed ID: 16831932
[TBL] [Abstract][Full Text] [Related]
2. [Bone disease in multiple myeloma and its mechanism].
Abe M
Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
[TBL] [Abstract][Full Text] [Related]
3. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
Giuliani N; Colla S; Rizzoli V
Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
[TBL] [Abstract][Full Text] [Related]
4. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
5. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Oyajobi BO; Mundy GR
Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
[TBL] [Abstract][Full Text] [Related]
6. Evidence of a role for RANKL in the development of myeloma bone disease.
De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
[TBL] [Abstract][Full Text] [Related]
7. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
Adamopoulos IE; Wordsworth PB; Edwards JR; Ferguson DJ; Athanasou NA
Hum Pathol; 2006 Sep; 37(9):1176-85. PubMed ID: 16938523
[TBL] [Abstract][Full Text] [Related]
8. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Tanaka S; Nakamura K; Takahasi N; Suda T
Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
[TBL] [Abstract][Full Text] [Related]
9. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.
Tanaka Y; Abe M; Hiasa M; Oda A; Amou H; Nakano A; Takeuchi K; Kitazoe K; Kido S; Inoue D; Moriyama K; Hashimoto T; Ozaki S; Matsumoto T
Clin Cancer Res; 2007 Feb; 13(3):816-23. PubMed ID: 17289872
[TBL] [Abstract][Full Text] [Related]
10. [Mechanisms for formation of myeloma bone disease].
Yata K; Abe M; Matsumoto T
Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
[TBL] [Abstract][Full Text] [Related]
11. [Link between osteoclastogenesis, angiogenesis and myeloma expansion].
Abe M
Clin Calcium; 2008 Apr; 18(4):473-9. PubMed ID: 18379029
[TBL] [Abstract][Full Text] [Related]
12. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
Anandarajah AP; Schwarz EM
J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.
Blair JM; Zhou H; Seibel MJ; Dunstan CR
Nat Clin Pract Oncol; 2006 Jan; 3(1):41-9. PubMed ID: 16407878
[TBL] [Abstract][Full Text] [Related]
14. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
Yeung RS
J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
[No Abstract] [Full Text] [Related]
15. Rheumatic diseases: the effects of inflammation on bone.
Walsh NC; Crotti TN; Goldring SR; Gravallese EM
Immunol Rev; 2005 Dec; 208():228-51. PubMed ID: 16313352
[TBL] [Abstract][Full Text] [Related]
16. Osteoclast precursors, RANKL/RANK, and immunology.
Xing L; Schwarz EM; Boyce BF
Immunol Rev; 2005 Dec; 208():19-29. PubMed ID: 16313338
[TBL] [Abstract][Full Text] [Related]
17. Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption.
Cozzani M; Giovannini I; Naccari R; Penolazzi L; Lambertini E; Borgatti M; Piva R; Gambari R; Siciliani G
Prog Orthod; 2005; 6(2):238-47. PubMed ID: 16276433
[No Abstract] [Full Text] [Related]
18. Pathogenesis of myeloma bone disease.
Roodman GD
Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
[TBL] [Abstract][Full Text] [Related]
19. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
20. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]